Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Citigroup Analyst Says

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price objective increased by investment analysts at Citigroup from $31.00 to $32.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price target would suggest a potential upside of 123.15% from the stock’s previous close.

A number of other research analysts also recently commented on the stock. Robert W. Baird downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $40.00 to $16.00 in a research note on Thursday, September 3rd. Guggenheim cut their price target on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Bank of America lowered shares of Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Thursday, September 3rd. JPMorgan Chase & Co. lowered Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $80.00 to $36.00 in a research report on Thursday, September 3rd. Finally, Evercore cut Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 target price on the stock. in a report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $37.26.

Ultragenyx Pharmaceutical Stock Down 1.1%

Shares of NASDAQ:RARE traded down $0.16 during trading on Friday, reaching $14.34. The stock had a trading volume of 2,429,122 shares, compared to its average volume of 2,590,477. The business has a fifty day moving average price of $24.26 and a 200-day moving average price of $24.49. The stock has a market cap of $1.41 billion, a P/E ratio of -2.46 and a beta of 0.31. Ultragenyx Pharmaceutical has a fifty-two week low of $12.73 and a fifty-two week high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The company had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same quarter in the prior year, the company posted ($1.17) EPS. The business’s revenue for the quarter was up 28.5% compared to the same quarter last year. As a group, equities analysts forecast that Ultragenyx Pharmaceutical will post -3.98 EPS for the current year.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of RARE. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $355,746,000. Assenagon Asset Management S.A. grew its position in Ultragenyx Pharmaceutical by 1,030.4% in the first quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after acquiring an additional 2,057,951 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of Ultragenyx Pharmaceutical during the second quarter valued at approximately $38,347,000. GW&K Investment Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 19.6% during the fourth quarter. GW&K Investment Management LLC now owns 1,375,407 shares of the biopharmaceutical company’s stock worth $31,634,000 after purchasing an additional 225,238 shares in the last quarter. Finally, Jefferies Financial Group Inc. purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at $31,040,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: FAYUVI’s approval represents Ultragenyx’s second gene-therapy approval and sixth FDA approval overall. The company expects shipments to qualified treatment centers within 30–60 days and will provide patient-access assistance through its UltraCare program. Ultragenyx Announces Approval of FAYUVI
• Positive Sentiment: Clinical data showed a durable treatment effect and a 23.5-point cognitive-score advantage versus a natural-history cohort, supporting the potential for meaningful clinical benefit. Ultragenyx also received a Priority Review Voucher that could have strategic or financial value. FDA approves Ultragenyx gene therapy
• Positive Sentiment: Canaccord Genuity raised its price target from $37 to $39 and maintained a Buy rating, while Cantor Fitzgerald increased its target from $33 to $39 and assigned an Overweight rating. These revisions indicate improved analyst expectations following the approval.
• Positive Sentiment: The stock’s recent advance occurred on above-average volume, while favorable earnings-estimate revisions may support additional near-term momentum. Ultragenyx stock and earnings estimate revisions
• Neutral Sentiment: Ultragenyx set FAYUVI’s price at $3.95 million, creating substantial revenue potential per patient but also making insurance coverage, reimbursement, and treatment-center access critical to the launch.
• Negative Sentiment: FAYUVI carries important safety risks, including elevated liver enzymes, thrombocytopenia, infusion reactions, and a potential malignancy risk. Long-term commercial adoption and safety remain uncertainties.
• Negative Sentiment: A previously reported failed Angelman syndrome trial and a law-firm investigation into potential investor claims remain overhangs. In addition, reported insider activity consisted entirely of sales over the past six months.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company’s work includes therapies for genetic, metabolic and skeletal disorders, with an emphasis on conditions that have limited or no effective treatment options.

Ultragenyx’s marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Dojolvi (triheptanoin), a medical food for long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab), a treatment for homozygous familial hypercholesterolemia.